Today John Cumbers talks with Claire Aldridge, Chief Strategy Officer at FormBio. Together they will discuss Form Bio, the spin-out from Colossal Laboratories & Biosciences, cell and gene therapies, why they are so difficult to manufacture, and the regulatory environment for these technologies.

Check out this week’s sponsor: Molecular Assemblies

Claire Aldridge, Chief Strategy Officer at FormBio. Claire brings decades of experience facilitating the translation of scientific discoveries into patient and commercial benefits. Claire has leveraged her training as a translator to act as a liaison between scientists and non-scientists, effectively communicating the potential of science. Her career has focused on technology commercialization, improving patient outcomes, working with disease-specific nonprofits, venture philanthropy, and biotech and life science investing.

Claire has a Ph.D. from Duke University in the Department of Immunology and Program in Genetics, and her Bachelor of Science in Biomedical Science is from Texas A&M University. Since grad school, Claire has had an extensive career in the biotech industry, leading them to numerous successful endeavors.

Connect with Claire: @ClaireAldrige2

Connect with John: @johncumbers

Stay updated on the latest news in synthetic biology, check out our weekly newsletter, and follow us on social media:

Twitter | LinkedIn | Facebook

Be sure you make it to our SynBioBeta events! Click here for more information.

174: Is it Time to Quit My Job?